<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01091675</url>
  </required_header>
  <id_info>
    <org_study_id>GRE-2009-01</org_study_id>
    <secondary_id>2009-017309-12</secondary_id>
    <nct_id>NCT01091675</nct_id>
  </id_info>
  <brief_title>Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs</brief_title>
  <official_title>Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis (AS) and Inadequate Response to ≥2 Nonsteroidal Antiinflammatory Drug (NSAID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Foundation of Rheumatology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Foundation of Rheumatology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research is to assess the percentage of non-responders to ≥ 2 NSAIDs
      candidates a biological therapy that could adequately respond to treatment with etoricoxib
      This study confirm the result of a previous study in a wider similar population. Basing on
      previous results, the response rate will be assessed by ASASBIO criteria. The efficacy of the
      treatment with etoricoxib 90 mg will be assessed at week 4 in a population of patients with
      AS who didn't respond adequately to a previous therapy with ≥ 2 NSAIDs.

      Those patients that, based on the ASABIO criteria, achieved a sufficient clinical response
      will be followed until week 24 to asses the maintenance of the study drug effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Etoricoxib is an oral, selective cyclooxygenase 2 inhibitor approved for the symptomatic
      treatment of ankylosing spondylitis (AS) in Spain.

      Etoricoxib is a marketed product indicated for the relief of symptomatic osteoarthritis,
      rheumatoid arthritis, ankylosing spondylitis, pain and signs of inflammation associated with
      acute gouty arthritis. In ankylosing spondylitis,the recommended dose is 90 mg once daily.

      Clinical pharmacology studies demonstrate that Etoricoxib induce dose-dependent inhibition of
      COX-2 without inhibit COX-1, up to 150 mg daily dose.

      Etoricoxib did not inhibit the gastric synthesis of prostaglandin and had no effect on
      platelet function. Cyclooxygenase is responsible for the prostaglandin synthesis. Were
      identified two different isoforms of cyclooxygenase, COX-1 and COX-2. It has been shown that
      COX-2 is the major enzyme responsible for the synthesis of prostanoid mediators involved in
      pain, inflammation and fever.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Percentage of Patients Fulfilling the Assessment Study (ASAS) Response Criteria Were Determined</measure>
    <time_frame>the ASAS response were evaluated at week 2 and 4 and after 6 months treatment</time_frame>
    <description>BASDAI Bath Ankylosing Spondylitis Disease Activity Index, is the gold standard for measuring and evaluating disease activity in Ankylosing Spondylitis consists of a one through 10 scale which is used to answer 6 questions pertaining to the 5 major symptoms of AS.
BASDAI has been used to assess the efficacy of the treatment. Possible Patients were considerate respond to ASABIO criteria when presented a change of 2 in the BASDAI score range.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>etoricoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All the patients who fulfil the eligibility criteria will start a 4-week open label treatment period to evaluate the response to treatment with etoricoxib 90 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib</intervention_name>
    <description>Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.</description>
    <arm_group_label>etoricoxib</arm_group_label>
    <other_name>Arcoxia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients ≥ 18 years.

          2. Patients with diagnosis of AS (based on New York criteria) made ≥ 6 months prior to
             study start.

          3. Patient with axial involvement.

          4. Patients who have been treated with ≥ 2 documented NSAID with proven anti-inflammatory
             potency during at least 3 months at maximal recommended or tolerated doses prior the
             visit 1.

          5. Patients who demonstrate a Bath Ankylosing Spondylitis Disease Activity Index score of
             ≥ 4 (range 0-10).

        Exclusion Criteria:

          1. Patient that according to the investigator opinion is legally unable (i.e. mentally
             incapable person), with psychiatric disorder precedent, active psychosis or emotional
             problems at the moment to be enrolled in the study.

          2. Patient who is participating in a clinical study with a drug or experimental device or
             it was done within 4 weeks prior to the inform consent signature.

          3. Patient with a recent history (since last 5 years) of abuse or dependence to opiates,
             tranquilizer or drugs at the inform consent signature moment. Patient with a recent
             history (since last 5 years) of alcoholism or drug addiction.

          4. Patient with a history of neoplastic disease or malignant neoplasia ≤ 5 years prior to
             the inform consent signature, except basal cell or squamous cell cancer skin
             adequately treated or uterine cancer insitu without recurrence prior to study entry
             according to the investigator opinion. Patients with history of leukemia, lymphoma,
             malignant melanoma or myeloproliferative disease cannot participate at the study.

          5. Pregnancy, lactation or waiting to conceive a child

          6. Patient with history of disorders, treatments or laboratory abnormality that can
             interfere with the study results and study participation.

          7. Patient cannot comply with the study procedures, study calendar. Patient with plan of
             moving.

          8. Patients awaiting the legal assessment of the degree of disability or the permanent
             work disability

          9. Patients unable to respond to questionnaires (difficulty understanding and / or
             reading of questionnaires)

         10. Any other warning that, in the investigator opinion, could discourage the inclusion of
             the patient in the study.

         11. Patient to be treated with other drug which can modulate the pain perception

         12. Patients with AS associated disease (inflammatory bowel disease, psoriasis).

         13. Patients with active peripheral articular involvement defined by presence of
             peripheral arthritis.

         14. Patient with predominant enthesitis or an enthesis that, according to investigator's
             opinion, can confound the correct evaluation.

         15. Presence of extra-articular manifestations.

         16. Patients with fibromyalgia or other rheumatic disorders that could confound the
             evaluation of efficacy

         17. Patients with AS who received biologic therapy. Note: The use of approved nonstudy
             antirheumatic therapy at a stable dose(methotrexate, sulfasalazine) for 3 months prior
             to the study start will be allowed.

         18. Patients with AS who received active treatment with etoricoxib

         19. Hypersensitivity to the active substance or to any of the excipients

         20. Active peptic ulceration or active gastro-intestinal bleeding

         21. Patients with severe renal failure (creatinine clearance rate &lt; 30 ml/min)

         22. Congestive heart failure (NYHA II-IV)

         23. Established ischaemic heart disease or cerebrovascular disease

         24. Patients with severe hepatic dysfunction (serum albumin &lt;25 g/l or Child-Pugh score
             ≥10).

         25. Patients who have experienced bronchospasm, acute rhinitis, nasal polyps,
             angioneurotic oedema, urticaria, or allergic-type reactions after taking
             acetylsalicylic acid or NSAIDs including cyclooxygenase-2 inhibitors

         26. Patients with hypertension whose blood pressure is persistently elevated above
             140/90mmHg and has not been adequately controlled
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordi Gratacós, PhD/ MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parc Tauli Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo Collantes Estevez, PhD/ MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Reina Sofia Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xavier Juanola Roura, PhD/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bellvitge Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raimon Sanmartí Sala, PhD/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic i Provincial Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Mulero Mendoza, PhD/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Puerta de Hierro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Estefania Moreno Ruzafa, PhD/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Rafael Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis Francisco Linares Ferrando, PhD/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virgen de la Arrixaca Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rubén Queiro Silva, PhD/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asturias Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elia Brito Brito, PhD/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ramon y Cajal Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Alberto Montilla Morales, PhD/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Salamanca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Cruces Fernández Espartero, PhD/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General de Mostoles Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pilar Fernández Dapica, PhD/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital 12 de Octubre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosario García de Vicuña, PhD/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital de la Princesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosa Morlá, PhD/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sant Pau i Santa Tecla Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Hospital of Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parc Tauli Hospital</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sant Rafael Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic I Provincial Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellvitge Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reina Sofia University Hospital</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ramon Y Cajal Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital 12 Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puerta de Hierro Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General of Mostoles</name>
      <address>
        <city>Madrid</city>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital de la Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virgen de la Arrixaca Hospital</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic of Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sant Pau i Santa Tecla Hospital</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Estévez, E. Collantes, and A. Escudero Contreras.</citation>
  </reference>
  <reference>
    <citation>Sociedad Española de reumatología: estudio EPISER. Prevalencia de las enfermedades reumáticas en la población española. Reumatología. Madrid, Merck, Sharp &amp; Dohme, 2001.</citation>
  </reference>
  <reference>
    <citation>van der Heijde D, Baraf HS, Ramos-Remus C, Calin A, Weaver AL, Schiff M, James M, Markind JE, Reicin AS, Melian A, Dougados M. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum. 2005 Apr;52(4):1205-15.</citation>
    <PMID>15818702</PMID>
  </reference>
  <reference>
    <citation>Jarrett SJ, Sivera F, Cawkwell LS, Marzo-Ortega H, McGonagle D, Hensor E, Coates L, O'Connor PJ, Fraser A, Conaghan PG, Emery P. MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis. 2009 Sep;68(9):1466-9. doi: 10.1136/ard.2008.092213. Epub 2008 Oct 24. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.</citation>
    <PMID>18952641</PMID>
  </reference>
  <reference>
    <citation>Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D; ASAS Working Group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2003 Sep;62(9):817-24. Review.</citation>
    <PMID>12922952</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2010</study_first_submitted>
  <study_first_submitted_qc>March 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2010</study_first_posted>
  <results_first_submitted>May 6, 2015</results_first_submitted>
  <results_first_submitted_qc>May 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2015</results_first_posted>
  <last_update_submitted>August 12, 2015</last_update_submitted>
  <last_update_submitted_qc>August 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ankylosing spondylitis</keyword>
  <keyword>biologic therapies</keyword>
  <keyword>ASAS</keyword>
  <keyword>ASASBIO</keyword>
  <keyword>etoricoxib</keyword>
  <keyword>NSAIDs</keyword>
  <keyword>COX-2 Inhibitor</keyword>
  <keyword>ARCOXIA 90 mg</keyword>
  <keyword>BASDAI Bath Ankylosing Spondylitis Disease Activity Index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoricoxib</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study enrolled 58 patients in total, with ankylosing spondylitis, and Inadequate response to ≥2 NSAIDs. Patients who met The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores of 4 or higher and all study criteria participate in the study and were randomized at 14 study sites. The last patient completed in May 2013.</recruitment_details>
      <pre_assignment_details>From a total of 58 patients recruited 1 did not met the exclusion criteria, so 57 patients start the first phase. 4 patients abandoned the study due to hypertension. 53 patients completed the first phase. 27 did not proceed to phase 2 due to lack of efficacy and 3 patients were withdraw due to hypertension. 23 patients complete the study period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Etoricoxib</title>
          <description>All the patients who fulfil the eligibility criteria will start a 4-week open label treatment period to evaluate the response to treatment with etoricoxib 90 mg.
Etoricoxib: Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57">7 patients leave the study due to hypertension, 27 patients withdrew due to lack of efficacy</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etoricoxib</title>
          <description>All the patients who fulfil the eligibility criteria will start a 4-week open label treatment period to evaluate the response to treatment with etoricoxib 90 mg.
Etoricoxib: Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>From a total of 58 patients recruited one did not met the exclusion criteria so 57 patients were included in the study.</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" lower_limit="23" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>the Percentage of Patients Fulfilling the Assessment Study (ASAS) Response Criteria Were Determined</title>
        <description>BASDAI Bath Ankylosing Spondylitis Disease Activity Index, is the gold standard for measuring and evaluating disease activity in Ankylosing Spondylitis consists of a one through 10 scale which is used to answer 6 questions pertaining to the 5 major symptoms of AS.
BASDAI has been used to assess the efficacy of the treatment. Possible Patients were considerate respond to ASABIO criteria when presented a change of 2 in the BASDAI score range.</description>
        <time_frame>the ASAS response were evaluated at week 2 and 4 and after 6 months treatment</time_frame>
        <population>Patients with physician-diagnosed Ankylosing Spondylitis at 6 months before study start</population>
        <group_list>
          <group group_id="O1">
            <title>Etoricoxib</title>
            <description>All the patients who fulfil the eligibility criteria will start a 4-week open label treatment period to evaluate the response to treatment with etoricoxib 90 mg.
Etoricoxib: Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>the Percentage of Patients Fulfilling the Assessment Study (ASAS) Response Criteria Were Determined</title>
          <description>BASDAI Bath Ankylosing Spondylitis Disease Activity Index, is the gold standard for measuring and evaluating disease activity in Ankylosing Spondylitis consists of a one through 10 scale which is used to answer 6 questions pertaining to the 5 major symptoms of AS.
BASDAI has been used to assess the efficacy of the treatment. Possible Patients were considerate respond to ASABIO criteria when presented a change of 2 in the BASDAI score range.</description>
          <population>Patients with physician-diagnosed Ankylosing Spondylitis at 6 months before study start</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="10" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from September 23rd 2010 until May 28th 2013</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Etoricoxib</title>
          <description>All the patients who fulfil the eligibility criteria will start a 4-week open label treatment period to evaluate the response to treatment with etoricoxib 90 mg.
Etoricoxib: Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>cavernous hemangioma</sub_title>
                <description>The investigator evaluated this serious adverse event SAE, as possibly related to the study drug, The patient already suffered from cavernoma pedunculi left quadrigeminy but was unknown until symptoms appearance. Was withdrawn from the study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>arterial hypertension</sub_title>
                <description>7 patients were withdrew from the study due to hypertension. 1 case certainly related to the study drug. 3 patients demonstrate seriousness grade 1, and grade 2 in 4 patients</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>cold</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jordi Gratacós Masmitjá</name_or_title>
      <organization>Unidad de Reumatología, Hospital Parc Tauli de Sabadell. Institut Universitari UAB</organization>
      <phone>937.23.10.10</phone>
      <email>jgratacosmas@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

